APERI PHARMACEUTICALS
APERI pharmaceuticals is a biotech in the launch phase developed around an oral biologics delivery platform. With already 2 patents filed and about 7 years of specific research and development we initially target the lucrative Rheumatoid arthritis market with an oral formulation of Adalimumab antibody (Humira). AP09 is a novel permeation enhancer and forms the cornerstone of our technology. It allows macromolecules to diffuse through the tight space between cells, known as tight junctions, where they won’t do it under normal conditions. AP09 adopts a unique, mechanism-based, target selective, trans-mucosal permeation enhancers that offer maximum safety index, highly reversible effect and can transport antibodies without causing any toxicity.
APERI PHARMACEUTICALS
Industry:
Biotechnology Medical Pharmaceutical
Address:
Chatelaine, Geneve, Switzerland
Country:
Switzerland
Total Employee:
1+
Status:
Active
Total Funding:
20 K CHF
Similar Organizations
Boston Pharmaceuticals
Boston Pharmaceuticals Provides Healthcare Services.
Gaia Medical Institute
Gaia Medical Institute is a biotech company.
i2 Pharmaceuticals
i2 Pharmaceuticals, a biopharmaceutical company.
Magpie Pharmaceuticals
Magpie Pharmaceuticals is a biotechnology company.
ZATA Pharmaceuticals
ZATA Pharmaceuticals is a biotech start-up company.
Investors List
Venture Kick
Venture Kick investment in Grant - APERI Pharmaceuticals
Venture Kick
Venture Kick investment in Grant - APERI Pharmaceuticals